Grannus Therapeutics
PrivateLast Round
VC Round
Feb 1, 2025
Total Funding Raised
$3.18M
Company Overview
Grannus Therapeutics operates in Healthcare & Life Sciences and is based in Indianapolis, Indiana. Its latest recorded funding round was a VC Round in February 2025.
Grannus Therapeutics is a biotechnology company that develops small molecule inhibitors targeting specific isoforms of the Hsp90 chaperone protein for the treatment of various solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Grannus Therapeutics Comparables
Compare Grannus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pfizer | 74% | |
| Biogen | 73% | |
| Madrigal Pharmaceuticals, Inc. | 72% |
For institutional investors. Book with your work email.
Grannus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Feb 1, 2025 | ||||
| Seed | Jan 12, 2022 | ||||
| Grant | Dec 14, 2021 |
For institutional investors. Book with your work email.
Grannus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| National Eye Institute (NIH) | Grant |
| Elevate Ventures | Convertible Debt |
| NIH RADx | Grant |
| Indiana Economic Development Corporation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2022
$1M raised with participation from pitroadfund.
- Dec 14, 2021
$397K raised from Indiana Economic Development Corporation and National Eye Institute.
For institutional investors. Book with your work email.
Grannus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Grannus Therapeutics's valuation, stock price, and market status.
Is Grannus Therapeutics a public or private company?
Grannus Therapeutics is a private company.
What is the current stock price of Grannus Therapeutics?
Grannus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Grannus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Grannus Therapeutics worth (valuation)?
Valuation information for Grannus Therapeutics is not publicly available.
Can I buy Grannus Therapeutics stock?
Grannus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Grannus Therapeutics's last funding round?
Grannus Therapeutics's most recent funding round was VC Round on February 1, 2025.
Who are the main investors in Grannus Therapeutics?
Key investors in Grannus Therapeutics include National Cancer Institute, National Eye Institute (NIH), Elevate Ventures, NIH RADx, Indiana Economic Development Corporation.
Will Grannus Therapeutics IPO soon?
No public IPO plans have been announced for Grannus Therapeutics.
How can I track Grannus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Grannus Therapeutics's shares on secondary markets.